Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 11
Submit an article Journal homepage
1,782
Views
6
CrossRef citations to date
0
Altmetric
Oncology

Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States

Jinan Liua Value, Evidence, and Outcomes, GSK, Collegeville, PA, USACorrespondence[email protected]
,
Bruno Emondb Analysis Group, Montreal, Quebec, Canada
,
Eric M. Maiesec Value, Evidence, and Outcomes, GlaxoSmithKline, Navy Yard, PA, USA
,
Marie-Hélène Lafeuilleb Analysis Group, Montreal, Quebec, Canada
,
Patrick Lefebvreb Analysis Group, Montreal, Quebec, Canada
,
Isabelle Ghelerterb Analysis Group, Montreal, Quebec, Canada
,
Caterina Wud Analysis Group, Menlo Park, CA, USA
,
Jean A. Hurteaue US Medical Affairs, Women’s Oncology Portfolio, GSK, Waltham, MA, USA
&
Premal H. Thakerf Department of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA
 show all
Pages 1935-1945 | Received 21 Jan 2022, Accepted 09 Aug 2022, Published online: 27 Aug 2022

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
  • Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
  • Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–279.
  • Di Tucci C, Capone C, Galati G, et al. Immunotherapy in endometrial cancer: new scenarios on the horizon. J Gynecol Oncol. 2019;30(3):e46.
  • Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–2992.
  • Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol. 2020;152:102973.
  • Gravbrot N, Gilbert-Gard K, Mehta P, et al. Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumors. Antibodies (Basel). 2019;8(4):51.
  • Akada K, Koyama N, Miura T, et al. Real-world database analysis of the characteristics and treatment patterns of patients with endometrial cancer in Japan. Curr Med Res Opin. 2021;37(7):1171–1178.
  • Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389–393.
  • Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59(4):650–653.
  • Matoda M, Tanigawa T, Omatsu K, et al. Platinum-free interval in second-line chemotherapy for recurrent cervical cancer. Int J Gynecol Cancer. 2013;23(9):1670–1674.
  • Matoda M, Omatsu K, Yamamoto A, et al. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer. Eur J Gynaecol Oncol. 2014;35(3):224–229.
  • Rubinstein M, Halpenny D, Makker V, et al. Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the Memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep. 2019;28:120–123.
  • Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/intergroup study. Gynecol Oncol. 2013;131(3):567–573.
  • Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
  • Choi MC, Moon YW, Jung SG, et al. Real-world experience with pembrolizumab treatment in patients with heavily treated recurrent gynecologic malignancies. Yonsei Med J. 2020;61(10):844–850.
  • Kuznicki ML, Bennett C, Yao M, et al. Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population. Gynecol Oncol Rep. 2020;34:100671.
  • Rubinstein MM, Dickinson S, Narayan P, et al. Bevacizumab in advanced endometrial cancer. Gynecol Oncol. 2021;161(3):720–726.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.